Turn Therapeutics (NASDAQ:TTRX) Upgraded by D Boral Capital to “Strong-Buy” Rating

D Boral Capital upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a strong-buy rating in a research note published on Monday morning, MarketBeat Ratings reports.

Separately, D. Boral Capital initiated coverage on Turn Therapeutics in a report on Monday. They set a “buy” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Strong Buy” and a consensus target price of $8.00.

Turn Therapeutics Stock Up 18.2%

NASDAQ TTRX opened at $3.71 on Monday. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $26.50. The company has a 50 day simple moving average of $3.57.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.07) earnings per share for the quarter.

Insiders Place Their Bets

In other news, insider Abraham Chesed acquired 14,286 shares of the firm’s stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average cost of $4.60 per share, with a total value of $65,715.60. Following the acquisition, the insider owned 1,447,268 shares in the company, valued at approximately $6,657,432.80. This represents a 1.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Golden bought 9,868 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was purchased at an average price of $3.44 per share, for a total transaction of $33,945.92. Following the acquisition, the director directly owned 60,602 shares in the company, valued at approximately $208,470.88. This trade represents a 19.45% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 52,136 shares of company stock valued at $183,463 over the last 90 days.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.